Avricore Health's Net Loss Widens 59% Amidst Capital Raises

TL;DR

**AVCRF's deepening losses and reliance on equity raises a red flag; this stock is a speculative bet at best.**

AI Summary

Avricore Health Inc. reported a net loss of $1,677,000 for the fiscal year ended December 31, 2024, a significant increase from the net loss of $1,053,000 in 2023, reflecting a 59.26% deterioration. The company's accumulated deficit grew to $35,856,000 by December 31, 2024, up from $34,179,000 in 2023. Issued capital increased to $40,299,000 in 2024 from $39,649,000 in 2023, indicating some capital raising activities. Warrant reserves also saw an increase to $1,099,000 in 2024 from $1,009,000 in 2023. The company's strategic outlook appears focused on managing its capital structure and potentially expanding its system hardware and software offerings, as evidenced by the continued investment in these areas. However, the persistent net losses and growing accumulated deficit highlight ongoing challenges in achieving profitability and sustainable operations. The increase in issued capital and warrant reserves suggests reliance on equity financing to fund operations and growth initiatives.

Why It Matters

Avricore Health's widening net loss to $1,677,000 in 2024 from $1,053,000 in 2023 signals continued operational challenges, which could impact investor confidence and future funding rounds. For employees, sustained losses may raise concerns about job security and the company's long-term viability. Customers might see potential disruptions if the company struggles to maintain its service levels or invest in new technologies. In the competitive pharmaceutical preparations sector, Avricore's financial performance lags, potentially hindering its ability to compete with more financially robust players and innovate effectively.

Risk Assessment

Risk Level: high — The company reported a net loss of $1,677,000 in 2024, a 59.26% increase from the $1,053,000 loss in 2023, and an accumulated deficit of $35,856,000. These figures indicate significant financial instability and a high risk of continued losses, making it a high-risk investment.

Analyst Insight

Investors should exercise extreme caution and conduct thorough due diligence before considering Avricore Health Inc. stock. The persistent net losses and growing accumulated deficit suggest a challenging path to profitability, making it suitable only for investors with a high-risk tolerance.

Key Numbers

• $1.68M — Net Loss (Increased by 59.26% from $1.05M in 2023 to $1.68M in 2024.)
• $35.86M — Accumulated Deficit (Grew from $34.18M in 2023 to $35.86M in 2024, indicating persistent losses.)
• $40.30M — Issued Capital (Increased from $39.65M in 2023 to $40.30M in 2024, suggesting equity financing.)
• $1.10M — Warrant Reserve (Increased from $1.01M in 2023 to $1.10M in 2024, reflecting warrant issuances.)
• 59.26% — Increase in Net Loss (Percentage increase in net loss from 2023 to 2024.)

Key Players & Entities

• Avricore Health Inc. (company) — filer of the 20-F form
• SEC (regulator) — recipient of the 20-F filing
• $1,677,000 (dollar_amount) — net loss for fiscal year 2024
• $1,053,000 (dollar_amount) — net loss for fiscal year 2023
• $35,856,000 (dollar_amount) — accumulated deficit as of December 31, 2024
• $34,179,000 (dollar_amount) — accumulated deficit as of December 31, 2023
• $40,299,000 (dollar_amount) — issued capital as of December 31, 2024
• $39,649,000 (dollar_amount) — issued capital as of December 31, 2023
• $1,099,000 (dollar_amount) — warrant reserve as of December 31, 2024
• $1,009,000 (dollar_amount) — warrant reserve as of December 31, 2023

FAQ

Risk Factors

• Persistent Net Losses and Growing Accumulated Deficit [high — financial]: Avricore Health Inc. reported a net loss of $1,677,000 for the fiscal year ended December 31, 2024, a 59.26% increase from the $1,053,000 loss in 2023. The company's accumulated deficit has grown to $35,856,000, indicating a continued struggle to achieve profitability and sustainable operations.
• Reliance on Equity Financing [medium — financial]: The increase in issued capital to $40,299,000 in 2024 from $39,649,000 in 2023, along with an increase in warrant reserves to $1,099,000 from $1,009,000, suggests that the company is relying on equity financing to fund its operations and growth initiatives. This can dilute existing shareholders and increase financial risk if not managed effectively.
• Investment in System Hardware and Software [medium — operational]: The company continues to invest in system hardware and software offerings. While this indicates a strategic focus on expanding these areas, the success and return on these investments are critical for future financial health, especially given the current net losses.

Industry Context

Avricore Health Inc. operates within the pharmaceutical preparations sector (SIC 2834). This industry is characterized by significant research and development costs, stringent regulatory oversight, and a competitive landscape driven by innovation and market access. Companies in this space often require substantial capital to fund product development and commercialization.

Regulatory Implications

As a pharmaceutical company, Avricore Health Inc. is subject to extensive regulatory scrutiny from bodies like Health Canada and the FDA. Compliance with Good Manufacturing Practices (GMP) and other health regulations is critical. Any failure to comply can result in significant fines, product recalls, or suspension of operations.

What Investors Should Do

1. Monitor progress towards profitability
2. Evaluate the effectiveness of equity financing
3. Assess the strategic investments in hardware and software

Glossary

Accumulated Deficit

The cumulative total of net losses over a company's history, minus any net profits. A negative retained earnings balance. (Indicates the company has historically incurred more losses than profits, with the deficit growing to $35,856,000 in 2024.)

Issued Capital

The total value of shares that a company has issued to investors. It represents the equity financing raised by the company. (Increased to $40,299,000 in 2024, showing ongoing equity fundraising efforts.)

Warrant Reserve

Represents the value attributed to warrants issued by the company, which give holders the right to purchase shares at a specified price. (Increased to $1,099,000 in 2024, suggesting the issuance of more warrants, often tied to financing rounds.)

Year-Over-Year Comparison

For the fiscal year ended December 31, 2024, Avricore Health Inc. reported a net loss of $1,677,000, a significant 59.26% increase from the $1,053,000 loss in 2023. The accumulated deficit also grew from $34,179,000 to $35,856,000. While issued capital increased to $40,299,000 and warrant reserves to $1,099,000, reflecting continued equity financing, the company's financial performance shows a worsening trend in profitability.

Filing Details

This Form 20-F (Form 20-F) was filed with the SEC on June 16, 2025 regarding Avricore Health Inc. (AVCRF).

View full filing on EDGAR

View Full Filing

View this 20-F filing on SEC EDGAR